Datum a Místo narození :  21 May 1957, Zagreb, Chorvatsko  -  Národnost :  Německá

​

AKADEMICKÉ A PROFESIONÁLNÍ VÝSLEDKY:

1983                 M.Sc. in Biology, Justus-Liebig-University, Giessen, Germany
1983 – 1985     Scientist at the Institute of Virology, Justus-Liebig-University, Giessen, Germany,                           (Lab. Heinz Bauer - cancer immunology)

1985 – 1988     Scientist at the Laboratory for Molecular Biology of the Ludwig-Maximilians-                                 University, Munich, Germany, (Lab. Elisabeth Weiss - cancer immunology, AIDS)

1989                 Ph.D. in Molecular Biology, Ludwig - Maximilians - University, Munich, Germany

1989                 Post-doctoral Research Fellow at Sandoz Research Institute, Vienna, Austria,                               Dept. Immunostimulation 
1990 – 1996     Laboratory Head, Dept. of Anti-Retroviral Therapy and Gene Therapy (Joachim                           Hauber, Roelf Datema) at Sandoz Research Institute, Vienna, Austria
1996 – 1997     Head of Molecular Biology Group, Department of Immuno-dermatology                                       (Thomas Baumruker – drug discovery and profiling, nuclear transport) at                                     Sandoz Research Institute, Vienna, Austria

1997                 Dr. habil. in Human Virology – on prevention of HIV 1 replication, University of                               Vienna, Austria
1997 – 1999     Program Team Head, Department of Immunology (Jan de Vries – drug                                         discovery and profiling), Novartis  Research Institute, Vienna, Austria

1999 – 2001     Laboratory Head (1999); Head of Platform Technologies (2000);

                         Vice President Research (2001) (Axel Ullrich) at VirGene/Axxima                                                   Pharmaceuticals AG, Martinsried, Germany – set-up and performing of                                         preclinical and 1 clinical phase II trial for AIDS

2001 – 2016     Chief Scientific Officer of mondoBIOTECH/THERAMetrics, Stans, Switzerland –                           set-up and performing preclinical and 5 different clinical trials phase II with                                 inhaled drugs for Pulmonary Hypertension, Pulmonary Fibrosis, and                                             Sarcoidosis 
2002                 Collaboration with InterMune, Inc., Brisbane, CA, for clinical development of                                 Interferon gamma for Severe Asthma
2005 – 2009     CEO of TheraNostics GmbH, a full subsidiary of mondoBIOTECH, Martinsried,                             Germany
2010 – 2011     Biomedical Scientific Advisor to Cecil H. Green Library, Stanford University,                                 Stanford, CA 
2015 – 2016     Member of the Task Force at International Rare Diseases Research Consortium                           IRDiRC   

2016 – 2017     Chief Development Officer at THERAMetrics Discovery AG, Stans, Switzerland

2012 – today    Scientific Advisor to the German Transregional Collaborative Research                                         Consortium 84 (SFB-TR 84): Innate Immunity of the Lung - Mechanisms of                                   Pathogen Attack and Host Defence in Pneumonia 

2017 – today    Scientific Advisor to the Artificial Intelligence company AI VIVO, Cambridge, UK 

​

2017 – 2019     Member of Scientific Advisory Board of the Artificial Intelligence company                                   Yewno, Inc., Redwood City, CA 

2017 – today    Scientific Advisor to the German Nebulizer company Nebu-tec 

2017 – today    Scientific Advisor to the National Scientific Center for Oncology at Tashkent,                                 Uzbekistan 

2001 – today    Member or associate to patient advocacy groups for: 
                         Pulmonary Arterial Hypertension https://www.phev.de/ 
                         Behcet Disease https://behcets.org.uk
                         Dravet Syndrome https://www.dravetfoundation.org 
                         Narcolepsy http://julieflygare.com/category/narcolepsy-not-alone/

                         Parkinson´s Disease https://www.cureparkinsons.org.uk/ 
                         Neuromyelitis Optica https://guthyjacksonfoundation.org/ 

2018 – 2019     Business Development Associate of apeptico GmbH, Vienna, Austria

2018 – today    Co-founder of BBiotica GbR Healthcare&Lifestyle company, Bad Nauheim,                                   Germany

2019 – today    Scientific Advisor to the Artificial Intelligence company OakLabs                                                   https://www.oak-labs.com/ Berlin, Germany

2019 – today    Scientific Advisor to the Biotech company ImmunoLogik 

                         Berlin & Erlangen, Germany 

2019 – today    Head of Drug Discovery and Scientific Commercialization at                                                         MetrioPharm/Athenion Group,  Zürich & Berlin 
   

2020 – today    Scientific Advisor to the Biotech Company AdVita Lifescience GmbH,                                           Denzlingen, Germany

2020 – today    Co-founder of Healthcare Company BiYottica UG, Frankfurt/Main, Germany

2020 – today    Co-founder of Nutrition Company Nutri4Global AG, Baar, Switzerland

2020 – today    Co-founder of Company for new Fitness, Healthcare, and Nutrition NextLevel                               Tec UG, Frankfurt/Main, Germany

2021                 Co-founder of Nutrition Company DORIJAN s.r.o., Castle Nalzovy 1, Czech

​

​

     VÝBĚR NĚKTERÝCH OCENĚNÍ

​

1992               “Preis der Hoechst-Stiftung zur Förderung der medizinischen Forschung in                                    Österreich” as Co-author on a scientific publication

1992               “Wolfgang Denk-Preis 1992 der Österreichischen Gesellschaft für Hämatologie                            und Onkologie” as Co-author on a scientific publication

1998               “Theodor Billroth Preis der Österreichischen Ärztekammer” as Co-author on a                                scientific publication

2008               “Technology Pioneer 2008” by the World Economic Forum for the establishment                            of the company mondoBIOTECH

2013               “Certificate of Merit” by the Saudi Arabian Association for Pulmonary                                              Hypertension, Jeddah, Saudi Arabia

2015               “HH Prince Mansour Bin Bandar Alsaud Award” by the Saudi Association for                                Pulmonary Hypertension for “Aviptadil in Pulmonary Hypertension”, Abu Dhabi,                            United Arab Emirates
2017               “HH Prince Mansour Bin Bandar Alsaud Award” by the Saudi Association for                                Pulmonary Hypertension for “Aerosolized B-type natriuretic peptide for the                                  treatment of Tuberculosis-associated Pulmonary Hypertension”, Dubai, UAE

2018               “Certificate of Merit” by the Sudanese Chest Physician Society, Khartoum, Sudan

2018                Semifinalist at IPIEC GLOBAL 2018 organized by WTOIP, Huangpu District,                                  Guangzhou, Guangdong Province, P.R. China, 

2019                Quarterfinalist at IPIEC GLOBAL 2019 organized by WTOIP, Huangpu District,                            Guangzhou, Guangdong Province, P.R. China

VÝBĚR NĚKTERÝCH PATENTŮ

​

European patent EP 1255541: Aromatic guanylhydrazones for the treatment of resistant viral                                                       infections.

European patent EP 1420778: Use of MEK inhibitors for treating virus induced hemorrhagic                                                         shock or fever.

USA patent US8541364; European patent EP 2188016 Japanese patent 5385280:

                                                 Octreotide for the treatment of Mycobacterium tuberculosis                                                           infections.

USA patent US 8349805; Japanese patent 5385279: Gonadorelin for the treatment of                                                                   Mycobacterium tuberculosis infections.

USA patent US 8338380; European patent EP 2187913; Japanese patent 5385281: Acetalin 2                                                     for the treatment of Mycobacterium tuberculosis infections.

USA patent US 6849409:         Cellular kinases involved in Cytomegalovirus infection and their                                                     inhibition.

European patent EP 1855661; People’s Republic of China patent CN 101247794; Australian patent AU 2006 222233; Indian patent IN 1363 MUMNP 2007; USA patent US 8178489; Mexican patent MXa2007010930: Formulation for Aviptadil.

​

European patent EP 1515745; USA patent US 7951778; People’s Republic of China patent CN 1313149; Australian patent AU 2003 236072; Canadian patent CA 2488358; Hong Kong patent HK 7112890.9:                   Aviptadil for the treatment of Sarcoidosis.

​

European patent EP 164028; USA patent US 7468353; People’s Republic of China patent CN 1917898; Australian patent AU 2004 255379:

                                          Aviptadil for the treatment of Interstitial Lung Diseases.

​

European patent EP 2197477; Japanese patent 5395793: Leu-Valorphin-Arg for the treatment                                                     of Mycobacterium tuberculosis infections.

European patent EP 2187915; Japanese patent 5384501: Renin inhibitor PHPFHLFVY for the                                                       anti-angiogenesis treatment of certain diseases.

USA patent US 8193149; Japanese patent 5385278: Use of Peptide YY, alone or in                                                                       combination with Glucagon-like peptide, for use in medicine.

USA patent US 8211856; European patent EP 2190535; Japanese patent 5384502: Use of                                                           Somatostatin-14 as a therapeutic agent.

European patent EP 2187954: Alpha melanocyte stimulating hormone for the treatment of                                                           chronic beryllium disease.

European patent EP 2187901; Japanese patent 5385276: Neuropeptide EI, optionally together                                                   with ACTH (7-38) for the anti-angiogenesis certain diseases.

European patent EP 2190447; Japanese patent 5480140: Stresscopin-related peptide for the                                                       anti-angiogenesis treatment of certain diseases.

European patent EP 2187840; Japanese patent 5385283: Use of Urocortin for treating and                                                           preventing hepatitis B virus infection.

Japanese patent 5385284:      Use of Exorphin C for the anti-angiogenesis treatment of certain                                                   diseases.

Japanese patent 5395792:      Use of Astressin for the anti-angiogenesis treatment of certain                                                       diseases.

Japanese patent 539    5794:  Use of Galanin for the anti-angiogenesis treatment of certain                                                         diseases.

Japanese patent 5385282:      Use of Pro-Ser-Hyp-Gly-Asp-Trp for the anti-angiogenesis                                                             treatment of certain diseases.

Japanese patent 5385277:      Use of Proadrenomedullin for the treatment of Mycobacterium                                                       tuberculosis infections.

Japanese patent 5491396:      Use of Defensin HNP2 for the anti-angiogenesis treatment of                                                         certain diseases.

European patent EP 1455813: Interferon gamma in combination with a diagnostic array for use                                                   in the improved treatment of idiopathic pulmonary fibrosis.​

​

Patent vyhledávání pro Dr. Dorian Bevec at Espacenet:

https://worldwide.espacenet.com/searchResults?submitted=true&locale=en_EP&DB=EPODOC&ST=advanced&TI=&AB=&PN=&AP=&PR=&PD=&PA=&IN=dorian+bevec&CPC=&IC=&Submit=Search 

 

​

AUTOR NĚKOLIKA PŘÍSPĚVKŮ A ODBORNÝCH PUBLIKACÍ

​

                    Adopted Orphan Drug Designations European Medicine Agency – EMA
                    Food and Drug Administration of the United States of America – FDA 

​

2003 EMA:   for inhaled Aviptadil in Pulmonary Arterial Hypertension and Chronic                                             Thromboembolic Pulmonary Hypertension 

2005 FDA:    for inhaled Aviptadil in Pulmonary Arterial Hypertension 22/02/2005

2005 EMA:   for inhaled Interferon gamma in Idiopathic Pulmonary Fibrosis (EU/3/05/281)

2006 EMA:   for Aviptadil in Acute Lung Injury (EU/3/06/395)

2007 EMA:   for inhaled Aviptadil in Sarcoidosis (EU/3/07/473)

2007 FDA:    for inhaled Interferon gamma in Idiopathic Pulmonary Fibrosis 10/11/2007

2010 FDA:    for alpha-Melanotropin in Chronic Beryllium Disease 02/09/2010

2011 FDA:    for Thymopentin in Sarcoidosis 04/02/2011

2011 FDA:    for Peptide YY in Hepatitis B Virus-induced Hepatocellular Carcinoma 18/04/2011

​

                                                           Clinical trial monitor
2001 – 2005 at mondoBIOTECH
                    Clinical monitor of clinical trials in chronic lung diseases (Asthma, Pulmonary                              Arterial Hypertension, Sarcoidosis, Idiopathic Pulmonary Fibrosis)

                    Teaching courses and workshop activities
1988 – 1999 at Sandoz/Novartis Research Institute, and VIRCC (Vienna International Research                       Cooperation Center), Vienna, Austria:
                     Organized and held on regular basis teaching courses for laboratory technical                             staff members and medicine students concerning following topics:

​

1) Molecular and Cellular techniques 
2) Basic courses from DNA to protein in physiological and pathological settings
3) Molecular immunology and pharmacology of immune-stimulating and immunosuppressing        agents
4) Molecular biology of regulatory proteins Tat, Tax, Rev, Rex from human retroviruses as                antiviral pharmaceutical intervention targets
5) Molecular biology and pharmacology of nuclear import and nuclear export modifiers in the         field of immunology

​

2001 – 2011 at mondoBIOTECH workshops in Switzerland and Germany:
                     Workshops for clinical and scientific experts concerning following topics

1) Molecular biology, pharmacology, non-clinical toxicology, design of clinical trials, regulatory        requirements, and business considerations for the use of inhaled and systemic human                peptides as potential drugs for the treatment of:
    Pulmonary Arterial Hypertension
    Mycobacterium tuberculosis infections
    Sarcoidosis
    Acute lung injury
    Chronic Beryllium disease
    Lymphangioleiomyomatosis
    Childhood epilepsies
    Asbestosis
    Mesothelioma
    Hepatitis B Virus infections 

a mnoho dalších.......